A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150]

Official Title

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Summary:

This randomized, open-label study will evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin and paclitaxel with or without bevacizumab compared with treatment with carboplatin plus (+) paclitaxel and bevacizumab in chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).

Trial Description

Primary Outcome:

  • Progression Free Survival (PFS) as determined by the Investigator using Response Evaluation Criteria in Solid Tumours (RECIST v1.1)
Secondary Outcome:
  • Objective Response as determined by the Investigator using RECIST v1.1
  • Overall Survival (OS)
  • Duration of response as determined by the Investigator using RECIST v1.1
  • PFS as determined by the Independent Review Facility using RECIST v1.1
  • OS at 1 and 2 Years
  • Time to deterioration (TTD) in patient-reported Lung Cancer Symptoms
  • Change from baseline in patient-reported Lung Cancer Symptoms
  • Safety: Incidence of Adverse Events

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society